Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use

U Marslew1, N Munk-Nielsen, L Nilas

  • 1Center for Clinical & Basic Research, Ballerup, Denmark.

Maturitas
|October 1, 1994
PubMed
Summary

This study compared four hormone therapy regimens for postmenopausal women. One regimen, 1.5 mg 17 beta-estradiol with 150 micrograms desogestrel [E2 + DG], offered the best bleeding control and symptom relief without breast tenderness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Bone·2018
Same author

Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study.

International journal of epidemiology·2016
Same author

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

Osteoarthritis and cartilage·2015
Same author

OA phenotypes, rather than disease stage, drive structural progression--identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA.

Osteoarthritis and cartilage·2015
Same author

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.

Bone·2012
Same author

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2011

Area of Science:

  • Reproductive Endocrinology
  • Pharmacology
  • Women's Health

Background:

  • Menopause is associated with climacteric symptoms and requires effective management.
  • Hormone replacement therapy (HRT) is a common treatment for menopausal symptoms.
  • Different combined estrogen-progestogen regimens vary in efficacy and side effect profiles.

Purpose of the Study:

  • To compare the bleeding patterns and relief of climacteric symptoms among four sequential combined estrogen and progestogen regimens.
  • To identify an optimal HRT regimen for postmenopausal women.

Main Methods:

  • A 12-24 month placebo-controlled study involving 143 healthy early postmenopausal women.
  • Four sequential combined estrogen and progestogen regimens were administered: 2 mg 17 beta-estradiol with 1 mg norethisterone acetate [E2 + NETA]; 2 mg estradiol valerate with 75 micrograms levonorgestrel [E2V + LNG]; 2 mg estradiol valerate with 10 mg medroxyprogesterone acetate [E2V + MPA]; and 1.5 mg 17 beta-estradiol with 150 micrograms desogestrel [E2 + DG].

Related Experiment Videos

  • Bleeding patterns, onset, and climacteric symptom relief were assessed.

    • Main Results:

    • Bleeding lengths were similar across regimens (3-6 days for most women).
    • Bleeding onset varied significantly, with the [E2 + DG] regimen showing 80% of women bleeding after progestogen addition.
    • All regimens effectively reduced climacteric symptoms, but only [E2 + DG] avoided breast tenderness.

    Conclusions:

    • While differences were not always conspicuous, the 1.5 mg 17 beta-estradiol with 150 micrograms desogestrel [E2 + DG] regimen demonstrated superior bleeding control.
    • The [E2 + DG] regimen provided optimal symptom relief and notably lacked the side effect of breast tenderness.
    • This suggests [E2 + DG] as a potentially preferred option for managing menopausal symptoms.